VJOncology is committed to improving our service to you

ASCO 2019 | Sunitinib for treating high-risk RCC

VJOncology is committed to improving our service to you

Daniel George

Daniel George, MD, of the Duke University Cancer Center, Durham, NC describes the key findings from a recent phase III trial of adjuvant sunitinib in the treatment of renal cell carcinoma at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter